Contact Lens Prescription Verification Modernization Act This bill revises the requirements for the verification of prescriptions related to the purchase of contact lenses. Specifically, online sellers of prescription contact lenses must provide consumers with a method to transmit a digital copy of their prescriptions to such sellers. Online sellers also must encrypt protected health information they send by email. Additionally, the bill prohibits any seller of prescription contact lenses from using telephone calls with an artificial or prerecorded voice (i.e., robocalls) to verify a consumer's prescription.
Helping Medicaid Offer Maternity Services Act of 2021 or the Helping MOMS Act of 2021 This bill permanently allows states to provide one year of postpartum coverage under Medicaid and temporarily increases the Federal Medical Assistance Percentage (i.e., federal matching rate) for pregnancy-related services in states that choose to do so.
Midwives for Maximizing Optimal Maternity Services Act of 2021 or the Midwives for MOMS Act of 2021 This bill establishes grants within the Health Resources and Services Administration (HRSA) for establishing or expanding midwifery programs at institutions of higher education and nursing schools. HRSA may prioritize funding for institutions that focus on increasing the number of midwife professionals from underrepresented groups and that promote practicing in areas with limited access to professional health care.
Surface Transportation Advanced through Reform, Technology, and Efficient Review Act 2.0 or the STARTER Act 2.0 This bill addresses provisions related to federal-aid highway, transit, highway safety, motor carrier, innovation, and resiliency programs of the Department of Transportation (DOT). It also sets forth requirements for the operation of railroad freight cars in the United States. For example, the bill extends FY2020 enacted levels through FY2026 for federal-aid highway, transit, and safety programs. DOT must provide competitive grants for projects to provide parking for commercial motor vehicles on the federal-aid highway system; establish a discretionary program to award competitive grants for eligible projects that encourage economic viability of the nation, a metropolitan area, or a region; create a public awareness campaign to reduce instances of driving while under the influence of prescription and over-the-counter medications; and promulgate regulations to implement an apprenticeship program for licensed commercial motor vehicle drivers under the age of 21. The bill also establishes new competitive grant programs to spur innovation of connected vehicle applications into operational deployments and to test the safe integration of automated driving system technologies into the on-road transportation system. Additionally, the bill addresses projects to improve the resiliency of federal-aid highways and bridges on and off the National Highway System. Further, the bill prohibits the operation of railroad freight cars in the United States that have been manufactured or assembled by certain foreign countries or that contain sensitive technology from such countries.
Transportation Infrastructure Finance and Innovation Act for Airports This bill makes certain airport projects eligible for funding under the transportation infrastructure finance and innovation program of the Department of Transportation (DOT), including projects for airport noise capability planning and for constructing gates and related areas at which passengers board or exit aircraft. DOT may provide funding for these projects only if all steel and manufactured goods used in the projects are produced in the United States, with specified exceptions.
SOS: Sustaining Outpatient Services Act This bill allows for payment under the Medicare prospective payment system for hospital outpatient department services of certain items and services that are furnished at off-campus outpatient departments. Specifically, the bill allows for payment of items and services for which payments to physician specialists (under the Medicare physician fee schedule) did not exceed $2 million during the previous year.
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2021 or the CHANGE Act of 2021 This bill modifies the requirements under Medicare for diagnosing and treating Alzheimer's disease and other cognitive impairments in older adults. Specifically, the bill expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated detection tools and documentation of the results in the patient's medical record. Further, when a cognitive impairment is detected, the patient must be referred to an appropriate diagnostic service provider and other specified supports. Additionally, the Centers for Medicare & Medicaid Services must implement Medicare policies that increase the identification and response to patients' Alzheimer's disease risk factors and incentivize providers to utilize high-quality cognitive impairment diagnosis practices. The Government Accountability Office also must conduct a study of policies that may accelerate progress in Alzheimer's disease research and enhance the quality of care for individuals diagnosed with Alzheimer's disease.
Fairness in Orphan Drug Exclusivity Act This bill limits which orphan drugs may be granted a market exclusivity period by the Food and Drug Administration (FDA). (Generally, an orphan drug is one that is not economically viable because of the rarity of the disease that it treats. The sponsor of an FDA-designated orphan drug may be granted various incentives, such as a seven-year period in which the FDA may not grant market approval to a different sponsor for the same drug to treat the same disease.) Under this bill, if a drug is designated as an orphan drug on the basis that there is no reasonable expectation that the sponsor will recover the costs of developing and distributing the drug from U.S. sales, the drug shall be granted the seven-year exclusivity period only if the sponsor demonstrates that there is no reasonable expectation that it will recover such costs specifically within its first 12 years of U.S. sales of the drug. This requirement shall also apply retroactively to an orphan drug that was granted such an exclusivity period before this bill's enactment. When deciding whether an orphan drug meets this requirement, the FDA shall consider the sales of all drugs from the sponsor that are covered by the same orphan drug designation.
This resolution affirms U.S. support for Israel's right to peace and security as well as its right to defend itself and its civilians against terror.
This resolution directs the Office of the Attending Physician to update the mask-wearing guidance (consistent with public guidance released by the Centers for Disease Control and Prevention) applicable to the Hall of the House of Representatives and committee meeting spaces for Members and staff who are vaccinated against COVID-19.
This resolution welcomes President Moon Jae-in of South Korea to the United States. It also reaffirms the importance of the U.S.-South Korea relationship to peace, security, and prosperity on the Korean Peninsula and in the Indo-Pacific region.
This resolution reaffirms the importance to U.S. national interests of combating corruption, strengthening democratic institutions, and supporting judicial independence in El Salvador. Further, it urges El Salvador to respect its democratic institutions, including by strengthening government transparency, and to uphold human rights.
